Drugs / VAROKIBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04847674 | May 2021 → Apr 2022 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | Missed primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAROKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314717 ↗ |
| Known as | TEV-53275 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04847674 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314717 ↗ |
| Route | Subcutaneous | “TEV-53275 administered subcutaneously (sc)” NCT04847674 ↗ |